Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v7-EN Version v2-FR
Language English French
Date Updated 2020-08-07 2020-07-16
Drug Identification Number 01927698 01927698
Brand name NOZINAN INJ 25MG/ML NOZINAN INJ 25MG/ML
Common or Proper name Nozinan inj 25mg/mL Nozinan inj 25mg/mL
Company Name SANOFI-AVENTIS CANADA INC SANOFI-AVENTIS CANADA INC
Ingredients METHOTRIMEPRAZINE METHOTRIMEPRAZINE
Strength(s) 25MG 25MG
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR INTRAVENOUS
Packaging size 10 amps 10 amps
ATC code N05AA N05AA
ATC description ANTIPSYCHOTICS ANTIPSYCHOTICS
Reason for shortage Other (Please describe in comments) Other (Please describe in comments)
Anticipated start date 2020-08-10 2020-08-10
Actual start date
Estimated end date 2020-08-21 2020-08-21
Actual end date 2020-08-07
Shortage status Avoided shortage Anticipated shortage
Company comments Product on allocation. Production delay. The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. Patients should validate the availability of the product with their respective pharmacy. Production delay. The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. Patients should validate the availability of the product with their respective pharmacy.
Health Canada comments